title: Effect of adapalene 0.1%/benzoyl peroxide 2.5% topical gel on quality of life and treatment adherence during long-term application in patients with predominantly moderate acne with or without concomitant medication - additional results from the non-interventional cohort study ELANG.
abstract: BACKGROUND
  In addition to physical long-lasting effects such as permanent scarring and disfigurement, acne has acute and long-term psychosocial effects that affect the individual's quality of life. As with other chronic diseases, treatment success is often compromised by poor adherence.
  
  
  OBJECTIVE
  Two main objectives of this non-interventional study were to assess the long-term effect of the fixed-dose combination adapalene 0.1%/benzoyl peroxide 2.5% (adapalene-BPO gel) on quality of life and treatment adherence.
  
  
  METHODS
  Patients with moderate to severe facial acne receiving adapalene-BPO alone or in combination with other drugs were enrolled in this non-interventional study. Data were documented at baseline and after 3 and 9 months of adapalene-BPO treatment. The secondary outcomes reported here include quality of life determined by the Cardiff Acne Disability Index (CADI), treatment adherence assessed by the ECOB (Elaboration d'un outil d'evaluation de l'observance des traitements medicamenteux) questionnaire, and patient satisfaction.
  
  
  RESULTS
  In total, 5131 patients were included in the efficacy evaluation. After 9 months, mean (±SD) quality of life (CADI) improved significantly from 5.9 ± 3.0 to 2.4 ± 2.7 (P < 0.0001). Patients with more severe acne at baseline tended to achieve a greater improvement in quality of life. Long-term adherence was found to be good in 83.9% of patients. Adherence had a significant effect on efficacy and quality of life (P < 0.0001 respectively). The vast majority of patients (92.1%) reported subjective improvement at the interim analysis. Accordingly, most patients (84.8%) were satisfied or very satisfied with adapalene-BPO by the end of the observation period.
  
  
  CONCLUSIONS
  The clinical improvement of the disease led to an increase in quality of life among acne patients. The treatment success may be a motivation factor for patients to stay adherent over the long-term treatment course, indicating the qualification of adapalene-BPO topical gel as an appropriate medication also in the long-term usage.
authors.affiliation: Department of Venereology and Dermatology, Otto-von-Guericke University Magdeburg, Germany.
authors.forename: H P M
authors.initials: HP
authors.lastname: Gollnick
authors.affiliation: Dermatologist in private practice Oranienburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Friedrich
authors.affiliation: Dermatologist in private practice Freiburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Peschen
authors.affiliation: Dermatologist in private practice Berlin, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Pettker
authors.affiliation: Dermatologist in private practice Lippstadt, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Pier
authors.affiliation: Dermatologist in private practice Buchholz in der Nordheide, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Streit
authors.affiliation: med:unit GmbH, Köln, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Jöstingmeyer
authors.affiliation: Galderma Laboratorium GmbH, Düsseldorf, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Porombka
authors.affiliation: Galderma Laboratorium GmbH, Düsseldorf, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Rojo Pulido
authors.affiliation: Galderma Laboratorium GmbH, Düsseldorf, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Jäckel
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000523:psychology; D000068816:Adapalene / Q000008:administration & dosage / Q000627:therapeutic use*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors; D055815:Young Adult; D016903:Drug Monitoring
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005782:Gels; D000068816:Adapalene; D001585:Benzoyl Peroxide